Translation and Psychometric Analysis of the Urdu Version of Stroke Specific Quality of Life Scale

September 12, 2023 updated by: University of Lahore

Translation, Cultural Adaptation and Psychometric Analysis of Urdu Version of Stroke Specific Quality of Life Scale in Stroke Patients

The leading cause of adult disability globally is stroke. Although stroke is rated as the third major cause of mortality in wealthy nations, it is the second major cause of mortality in developing nations. When creating a questionnaire for use in a different context, a procedure known as "cross-cultural adaptation" takes into account both linguistic (translation) and cultural adaption concerns. Beaten guidelines are standard to develop a questionnaire into a new language, measure it's psychometric properties and culturally adapt into a new population. By Williams, Weinberger, Harris, and Clark in 1999, the SS-QOL was published and verified for the first time. Since the Stroke Specific quality of life (SS-QOL) is meant to be self-administered, no training is necessary. According to one study, stroke victims can be accurately measured using the scale over the phone. The SS-QOL scale may be finished in 10 to 15 minutes. The SS QOL score increases with improved functioning. Cronbach's alpha values varied from satisfactory (alpha = 0.75 for the work/productivity subscale) to outstanding (alpha = 0.89 for self-care) in Williams' et al. (1999a) investigation of the internal consistency of the SS-QOL in 34 stroke patients, indicating that the SS-QOL has a good internal consistency. The present study endeavors to address this gap by translating the Stroke Specific Quality of Life questionnaire into Urdu, enabling a culturally adapted and accessible assessment tool. By assessing the validity of the obtained scores within the Pakistani population, this study aims to establish the reliability and effectiveness of the Urdu version. Consequently, this will serve to bridge the literature gap in stroke-related quality of life assessments among Urdu speakers in Pakistan. In doing so, this research strives to provide valuable insights and a comprehensive tool for clinical setups across diverse settings, urban or rural. By introducing a standardized gold standard test, healthcare professionals can confidently make accurate diagnoses and prognoses for their stroke patients. The Stroke Specific Quality of Life questionnaire, with its 49 self-report items encompassing 12 energy-related domains, is poised to contribute substantially to a more thorough understanding of stroke's impact on the quality of life within the Urdu-speaking population.

Study Overview

Status

Completed

Detailed Description

A cross-sectional study was conducted on 147 stroke patients at the Physiotherapy Department of the University of Lahore Teaching Hospital, located on Defense Road, Lahore. The study was completed within a span of 9 months following the approval of the research synopsis. A non-probability convenient sampling technique was employed for participant selection. The inclusion criteria encompassed patients who had been diagnosed with stroke, were aged between 35 to 65 years, and possessed the ability to comprehend and communicate verbally in the Urdu language. Conversely, patients with other neurological conditions such as Parkinson's disease, Alzheimer's disease, or dementia, as well as unconscious individuals, were excluded from the study. Additionally, patients with musculoskeletal and orthopedic conditions that could potentially impact the functioning of their upper and lower extremities were also excluded.

All patients provided written informed consent, and approval was obtained from the Ethics Committee of the University of Lahore. The translated Urdu version of the SS-QOL questionnaire was utilized for data collection, following a four-step procedure. Initially, two native Urdu speakers independently translated the SS-QOL into Urdu. One translator had medical expertise, while the other came from a non-medical background (T1, T2). Their translations were merged into a single version. Subsequently, this combined version was translated back into English by two professional translators (BT1, BT2) who were unfamiliar with the questionnaire and medical terminology, ensuring consistent English translation. A research committee comprising physiotherapists, an orthopedic surgeon, translators, a language expert, and authors held a meeting. This committee assessed all versions of the SS-QOL (T1, T2, T-12, BT1, BT2, B-12) for alignment with Urdu cultural nuances and methodological accuracy. They approved a pre-final SS-QOL version after methodological and grammatical analysis. Seventy patients confirmed their comprehension of the questions (pilot testing), and their feedback was deliberated upon by the authors. A final Urdu version of the SS-QOL was then established.

Study Type

Observational

Enrollment (Actual)

147

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab
      • Lahore, Punjab, Pakistan, 55150
        • University of Lahore Teaching hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Diagnosed Stroke Population within range of 35-65 years and possessed the ability to comprehend and communicate verbally in the Urdu language.

Description

Inclusion Criteria:

  • Diagnosed stroke patients
  • Age between 35 to 65 years 47
  • Patients should understand and can verbally communicate in Urdu

Exclusion Criteria:

  • Patient with other neurological conditions like parkinson, Alzheimer, Dementia etc
  • Unconscious patient
  • Patients with musculoskeletal and orthopedic conditions that affect upper and lower extremities function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short Form 12 (SF-12)
Time Frame: 1 week
The SF-12, or Short Form-12, is a widely used self-reported questionnaire used to assess health-related quality of life (HRQOL). It is a shorter version of the SF-36 (Short Form-36), which is a more extensive health survey. The SF-12 is designed to be a concise tool for measuring various aspects of a person's physical and mental health. The SF-12 questionnaire generates two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). These scores provide a way to interpret the overall health-related quality of life of an individual.
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Hafiza Sana Ashraf, MSPT MSK, The University of Lahore
  • Principal Investigator: Hafiza Maria Hira, MSPTN, The University of Lahore
  • Study Director: Umair Ahmed, PhD PT, The University of Lahore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2021

Primary Completion (Actual)

February 10, 2023

Study Completion (Actual)

April 1, 2023

Study Registration Dates

First Submitted

September 12, 2023

First Submitted That Met QC Criteria

September 12, 2023

First Posted (Actual)

September 21, 2023

Study Record Updates

Last Update Posted (Actual)

September 21, 2023

Last Update Submitted That Met QC Criteria

September 12, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

3
Subscribe